[3]. Garcia-Pavia P, et al. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021 Apr 21;42(16):1554-1568. [4]. Grogan M, et al. Natural History of Wild-Type Transthyretin Cardiac Amyloid...
amyloidosis, although treatment duration was unspeci-fied. The 2012 American College of Chest Physicians guidelines on antithrombotic therapy and prevention of thrombosis suggest at least 3 months of OAC therapy for LV thrombus in DCM (Grade 2C).4The consensus of this writing group, which is ...
Among patients with LV hypertrophy caused by cardiac amyloidosis, it has been reported that approximately 70% demonstrate a pattern of global subendocardial gadolinium enhancement, a pattern of enhancement not usually seen in patients with HCM (190). These data suggest that gadolinium-enhanced CMR ...
Recommendations for Treatment of Cardiac AmyloidosisReferenced studies that support the recommendations are summarized in the Online Data Supplements.COR LOE RECOMMENDATIONS1 B-R1. In select patients with wild-type or variant transthyretin cardiac amyloidosis and NYHA class I to III HFsymptoms, transthyret...
Among new recommendations for the treatment of amyloid heart disease are a diagnostic and therapeutic approach for cardiac amyloidosis that includes screening for monoclonal light chains and use of bone scintigraphy, genetic sequencing, anticoagulation therapy, and tetramer stabilizer therapy. Fin...
For more information, please go to Heart Failure, Atrial Fibrillation, Cardiac Amyloidosis, Hypertrophic Cardiomyopathy, Pacemakers and Implantable Cardioverter-Defibrillators, and Cardiac Resynchronization Therapy.Next: 2022 European Society of Cardiology Ventricular Arrhythmia Guidelines What...
n Cardiac amyloidosis. n Cardio-oncology. n Implantable devices. n Left ventricular assist device (LVAD) use in stage D HF. The intended primary target audience consists of cli- nicians who are involved in the care of patients with HF. ...
RecommendationsfortheInitialClinicalAssessmentofPatientswithHeartFailure心力衰竭患者初始临床评价UpdatestoInitialandSerialClinicalAssessmentsofPatientsPresentingwithHeartFailure2005GuidelineRecommendations2009FocusedUpdateRecommendationsCommentsClassIIaDiagnostictestsforrheumatologicdiseases,amyloidosis,orpheochromocytomaarereasonable...
or interest in alternative treatments. As the AHA statement emphasizes, although CAM should never replace standard guideline-directed and evidenced-based HF therapies, clinicians should discuss with interested patients when CAM therapy can be safely considered in conjunction with conventional treatment. ...
amyloidosis, eosinophilic myocarditis) are also important pathophysiological mediators in DCM that may increase the risk of LV thrombus formation. 31–36 However, data in relation to specific DCM causes are sparse on both LV thrombus risk and the impact on clinically relevant throm- ...